13F-HR filed by Versant Venture Management, LLC
Versant Venture Management, LLC filed this 13F-HR for the quarter ended 2020-03-31, filed 2020-04-28, with 9 holding rows worth $364,636,407.
- Accession
- 0001104659-20-052226
- Filer
- CIK 1560009
- Filed
- 2020-04-28
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2020
A holdings report, 9 entries on the cover page, a total value of $364,636,407 stated on the cover page (in dollars after the unit check, H1), rows summing to $364,636,407 with VALUE read as dollars, detected, 13F file number 028-16849. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 4,205,615 | $177,224,616 | dollars, detected | |
| Adverum Biotechnologies, Inc. | 00773U108 | Common Stock | 7,068,233 | $69,056,636 | dollars, detected | |
| AKERO THERAPEUTICS INC | 00973Y108 | COM | 2,736,572 | $58,015,326 | dollars, detected | |
| VERACYTE INC COM | 92337F107 | Stock | 1,205,407 | $29,303,444 | dollars, detected | |
| GRITSTONE BIO INC | 39868T105 | COM | 3,102,929 | $18,059,047 | dollars, detected | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 2,215,384 | $10,966,151 | dollars, detected | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 543,753 | $804,754 | dollars, detected | |
| CLOVIS ONCOLOGY INC | 189464100 | COM | 101,855 | $647,798 | dollars, detected | |
| SECOND SIGHT MED PRODS INC | 81362J100 | COM | 561,612 | $558,635 | dollars, detected |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-20-052226 | this filing | 2020-04-28 | acceptance time not in the bulk data set |